Characterization of the TAA-T product by phenotype and TCR clonotype diversity. (A) Variable composition of the TAA-T products by phenotype (CD8⁺, CD4⁺, NK [natural killer], TCRγδ [γ δ T cells], NKT [natural killer T cells]) presented as percent of total cells in product as determined by 12-color flow cytometry (n = 23). (B-C) Memory phenotype described as central memory (TCM; CD3⁺CD4/8⁺CD45RO⁺CCR7⁺CD62L⁺), effector memory (TEM; CD3⁺CD4/8⁺CD45RO⁺CCR7⁻CD62L⁻), and effector T cells (TEFF; CD3⁺CD4/8⁺CD45RO⁻CCR7⁻CD62L) for evaluable samples (n = 11). (D) Diversity of TCR sequences of TAA-T products shown for representative patients in the relapsed group (P9, P3) and patients treated preemptively with TAA-T products (P12, P13).